Efficacy of a Prescription-Based Mobile Digital Therapeutic as an Adjunct to Pharmacotherapy for the Acute Phase of Panic Disorder: Multicenter Randomized Controlled Trial.

J Med Internet ResOct 5, 2026 (epub)
Clinical ResearchPsychiatry

Yujin Ko, Junhyung Kim, Sunyoung Park et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial evaluated the efficacy of a prescription-based mobile digital therapeutic (DTx) as an adjunct to pharmacotherapy in 66 patients with acute-phase panic disorder. The DTx group demonstrated a significantly greater reduction in Panic Disorder Severity Scale-Self Report (PDSS-SR) scores at week 8 (40.29% vs 17.61%; P = .007), indicating its potential to enhance treatment outcomes.

Key findings

  • The DTx group had a 40.29% reduction in PDSS-SR scores at week 8 compared to 17.61% in the control group (P = .007).
  • By week 2, the DTx group showed a 26.66% reduction in PDSS-SR scores versus 11.05% in the control group (P = .02).
  • The responder rate (≥40% PDSS-SR reduction) was 53.12% in the DTx group compared to 17.24% in the control group (P = .007).
  • Overall mean adherence to the DTx was 78.12%, with no significant difference between responders and nonresponders.

Why it matters

The findings suggest that integrating a mobile DTx with pharmacotherapy can significantly improve symptom management in patients with acute-phase panic disorder, potentially leading to better patient outcomes and enhanced therapeutic strategies.

Source

PubMed · PMID 42832728

Published in J Med Internet Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.